Grateful to all the longs here. Have been since I

Quote:

---

Grateful to all the longs here. Have been since I first jumped in.

Had crazy anxiety last week in anticipation of results. All of it dissolved after I watched the proactive video.

---

The exact same thoughts and sentiments apply to me.

I am very grateful for this community of impressively intelligent and respectful members -- as well as for last night's video.

We are operating on some big assumptions, not the least of which are:

- Exactly how strong are the M/M results?
- How will the FDA rule on the M/M indication?
- Will the DSMC terminate the S/C due to overwhelming benefit?

However, Dr.NP has effectively telegraphed that the M/M results are very favorable and "beautiful times" are potentially right around the corner. And that alone removes a lot of the anxiety some of us have been feeling as we approach the COVID finish line.

If this is true, CytoDyn's time and resource gamble on the COVID indication will have completely changed the trajectory angle (and possibly the fate) of the company.

Think about this just for a moment:

- We have an investment bank
- We are going to uplist
- We are going to have revenue
- We will have institutional investors
- We have learned so much more about the MOA
- We will have peer reviewed papers on our molecule
- We will be known all around the world
- We will develop a favorable relationship with the FDA
- We will develop favorable relationships with FDAs all around the world
- We will have 10+ trials by the end of the year
- We will have Small & Big Pharma partnerships

Each one of the above items is a major corporate accomplishment.

And all of these herculean accomplishments will have occurred during a very compressed time frame that would have otherwise been a 'down interval' where the company would not have made much progress on clinical trials due to the pandemic.

Our little molecule is indeed very special. Say what you will, but our team led by Dr.NP seems to have made a perfect strategic decision to go after this indication.

And that decision will change the history of this company and the sick patients who are treated or healed by our mAb.

And by saving hundreds of thousands of lives, we will very possibly change the course of history.